The Lifestyle Disorders Market Outlook to 2014: Reimbursement issues, market dynamics, pipeline compounds
 
Table of Contents : 
“Table of Contents
The Lifestyle Disorders Market Outlook to 2014
Executive Summary 10
Lifestyle diseases – an overview 10
Global market analysis 11
Key investigational compounds 12
Competitive landscape 13
Scope and methodology 14
Scope 14
Methodology 14
Chapter 1 Lifestyle diseases – an overview 18
Summary 18
Introduction 19
Defining lifestyle diseases 20
Alcohol dependence 22
Chronic effects 22
Alopecia 23
Classification of Alopecia 23
Major depressive disorder (MDD) 24
Obesity 26
Causes of obesity 26
Hormonal contraception 28
 29
Smoking cessation 30
Quitting 31
Treatment 31
Characteristics of lifestyle drugs 32
Simple dosing regimen 32
Fast onset of action 33
Tolerable side effects 33
Epidemiology of lifestyle diseases 33
Reimbursement of lifestyle drugs 38
Reimbursement of in the US 38
Reimbursement of in the EU 39
Reimbursement of other lifestyle drugs – issues and challenges 41
Chapter 2 Global market analysis 44
Summary 44
Introduction 45
Key recent events 45
Swiss Competition Commission imposes penalty on leading players 45
Naltrexone not shown to be effective for substance abuse in schizophrenics 45
Xenical and Alli being assessed for risk of liver injury 46
The global contraceptives market still presents investment opportunities 46
Market analysis for leading lifestyle indications 47
Major depressive disorder (MDD) 48
Introduction 48
Analysis of drug classes 49
Leading treatment brands 51
Trends in generics usage 54
Hormonal contraception 54
Introduction 54
Analysis of drug classes 55
Leading treatment brands 56
Trends in generics usage 58
 58
Introduction 58
Analysis of drug classes 59
Leading treatment brands 60
Trends in generics usage 61
Smoking cessation 62
Introduction 62
Analysis of drug classes 62
Leading treatment brands 64
Trends in generics usage 65
Obesity 66
Introduction 66
Analysis of drug classes 67
Leading treatment brands 68
Trends in generics usage 70
Alcohol dependence 70
Introduction 70
Analysis of drug classes 71
Leading treatment brands 72
Trends in generics usage 73
Alopecia 73
Introduction 73
Analysis of drug classes 74
Leading treatments 75
Lifestyle disorders sales forecast 76
Leading brands dynamics 77
Leading brands sales forecasts 79
Chapter 3 Key investigational compounds 82
Summary 82
Introduction 83
Key trends in R&D 83
Obesity – different mechanisms of action being explored 83
Campral the first new drug in alcohol dependence in two decades 83
Vivitrol potential being explored in opioid dependence 84
Antabuse – a novel mechanism of action but presents compliance issues 84
Evolving novel mechanisms of action in the MDD market 84
Sanofi-Aventis terminated development of smoking cessation product
Dianicline 85
Profiles of leading drugs in development 85
Compounds awaiting regulatory approval compounds 86
WC 3016 (Norethindrone/ethinyl estradiol) – Warner Chilcott 86
Qnexa (phentermine/topiramate) – Vivus 88
APD356 (lorcaserin) – Arena 89
Phase III compounds 91
Contrave (bupropion/naltrexone) – Orexigen 91
The increasingly competitive obesity environment 92
Vilazodone – Clinical Data 94
F2695 (levomilnacipran) – Pierre Fabre/Forest 95
TA-1790 (avanafil) – Mitsubishi Tanabe/Vivus 96
NicVAX – Nabi Biopharmaceuticals/GSK 97
NIC002 (CYT002-NicQb) – Novartis/Cytos 99
Naltrexone depot – Elbion AG 100
Key investigational compounds sales forecast 101
Chapter 4 Competitive landscape 104
Summary 104
Introduction 105
Wyeth 108
Overview 108
Drug class focus 108
Marketed products portfolio 109
R&D pipeline analysis 110
Strategic growth analysis 110
Drivers of growth 110
Resistors to growth 111
Eli Lilly 111
Overview 111
Drug class focus 112
Marketed products portfolio 113
R&D pipeline analysis 114
Strategic growth analysis 114
Drivers of growth 114
Resistors to growth 115
Pfizer 115
Overview 115
Drug class focus 115
Marketed products portfolio 116
R&D pipeline analysis 118
Strategic growth analysis 118
Drivers of growth 118
Resistors to growth 118
Bayer 119
Overview 119
Drug class focus 119
Marketed products portfolio 120
R&D pipeline analysis 121
Strategic growth analysis 121
Drivers of growth 121
Resistors to growth 122
Forest 122
Overview 122
Drug class focus 122
Marketed products portfolio 123
R&D pipeline analysis 124
Strategic growth analysis 125
Drivers of growth 125
Resistors to growth 125
Dynamics of the leading alopecia market players 126
The competitive positioning of leading generic players 127
Chapter 5 Appendix 128
IMS data 128
Glossary 129
Index 131
List of Figures
Figure 1.1: Characteristics of lifestyle drugs 21
Figure 1.2: Causes of obesity 28
Figure 2.3: FDA approved indications of leading antidepressant brands, November 2009 49
Figure 3.4: Leading late-stage R&D products in the lifestyle disorders market, 2010 86
Figure 3.5: Comparative analysis of leading obesity pipeline compounds 93
Figure 4.6: Comparative positions of the top ten players, 2007–08 106
Figure 4.7: Drug class focus of Wyeth, 2008 108
Figure 4.8: Drug class focus of Eli Lilly, 2008 112
Figure 4.9: Drug class focus of Pfizer, 2008 116
Figure 4.10: Drug class focus of Bayer, 2008 119
Figure 4.11: Drug class focus of Forest, 2008 123
Figure 4.12: Comparative position of the leading generic players over the period 2004–08 127
List of Tables
Table 1.1: Classification of alopecia 24
Table 1.2: Forecast prevalence of obesity across seven major markets, 35
Table 1.3: Forecast prevalence of tobacco consumption across seven major markets, 2008–14 36
Table 1.4: Forecast prevalence of MDD across seven major markets, 2008–14 37
Table 2.5: The global lifestyle disorders market by indications ($m), 2007–08 48
Table 2.6: Sales performance of antidepressant drug classes, 2007–08 50
Table 2.7: The leading antidepressant brands, 2007–08 51
Table 2.8: Trends in generics usage in the antidepressants market, 2007–08 54
Table 2.9: Sales performance of hormonal contraceptive drug classes, 55
Table 2.10: The leading hormonal contraceptive brands, 2007–08 57
Table 2.11: Trends in generics usage in the hormonal contraceptives market, 2007–08 58
Table 2.12: Physical and psychological causes of ED 59
Table 2.13: The leading brands, 2007–08 60
Table 2.14: Trends in generics usage in the market, 62
Table 2.15: The leading smoking cessation brands, 2007–08 64
Table 2.16: Trends in generics usage in the smoking cessation market, 66
Table 2.17: The leading obesity brands, 2007–08 68
Table 2.18: Trends in generics usage in the obesity market, 70
Table 2.19: The leading alcohol dependence brands, 2007–08 72
Table 2.20: Trends in generics usage in the alcohol dependence market, 73
Table 2.21: The leading alopecia brands in the 7MM, 2007–08 76
Table 2.22: Lifestyle disorders market sales forecast by indication ($m), 77
Table 2.23: The leading alopecia brands, 2007–08 78
Table 2.24: Top 10 brands of the lifestyle disorders market sales forecast, 2008–14 79
Table 3.25: An overview of WC 3016 87
Table 3.26: An overview of Qnexa 88
Table 3.27: An overview of lorcaserin 90
Table 3.28: An overview of Contrave 91
Table 3.29: An overview of vilazodone 94
Table 3.30: An overview of F2695 95
Table 3.31: An overview of avanafil 96
Table 3.32: An overview of NicVAX 98
Table 3.33: An overview of NIC002 99
Table 3.34: An overview of naltrexone depot 1
 
 

For more information, please contact :